| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | VPS35/retromer complex |
| Diseases | Parkinson's Disease, Dementia with Lewy Bodies |
| Development Stage | Preclinical to Phase I |
| Mechanism | Endosomal trafficking, protein sorting, lysosomal function |
The [VPS35](/genes/vps35) gene encodes a critical component of the retromer complex, which is essential for endosomal sorting and protein trafficking throughout the cell. The D620N mutation in [VPS35](/genes/vps35) causes autosomal dominant [Parkinson's disease](/diseases/parkinsons-disease), establishing retromer dysfunction as a direct cause of neurodegeneration.
The retromer complex functions as a master regulator of intracellular trafficking, directing proteins from endosomes to the trans-Golgi network, plasma membrane, and lysosome. This function is particularly critical for [lysosomal](/mechanisms/lysosomal-dysfunction) and [autophagy](/mechanisms/autophagy-lysosomal-pathway-parkinsons) pathways that clear toxic protein aggregates in [neurodegeneration](/diseases/neurodegeneration).
The retromer consists of:
| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | VPS35/retromer complex |
| Diseases | Parkinson's Disease, Dementia with Lewy Bodies |
| Development Stage | Preclinical to Phase I |
| Mechanism | Endosomal trafficking, protein sorting, lysosomal function |
The [VPS35](/genes/vps35) gene encodes a critical component of the retromer complex, which is essential for endosomal sorting and protein trafficking throughout the cell. The D620N mutation in [VPS35](/genes/vps35) causes autosomal dominant [Parkinson's disease](/diseases/parkinsons-disease), establishing retromer dysfunction as a direct cause of neurodegeneration.
The retromer complex functions as a master regulator of intracellular trafficking, directing proteins from endosomes to the trans-Golgi network, plasma membrane, and lysosome. This function is particularly critical for [lysosomal](/mechanisms/lysosomal-dysfunction) and [autophagy](/mechanisms/autophagy-lysosomal-pathway-parkinsons) pathways that clear toxic protein aggregates in [neurodegeneration](/diseases/neurodegeneration).
The retromer consists of:
| Protein | Function |
|---------|----------|
| WASH complex | Actin polymerization, endosomal sorting |
| SNX proteins | Phosphoinositide binding, membrane deformation |
| TPCN2 | Calcium channel, lysosomal function |
The retromer traffics numerous proteins critical for neuronal function:
The D620N mutation (p.Asp620Asn) in [VPS35](/genes/vps35) causes:
The [retromer](/mechanisms/retromer-dysfunction) pathway is crucial for [alpha-synuclein](/proteins/alpha-synuclein) clearance: [@zavodszky2018]
| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| R55 | Retromer stabilizer | Preclinical |
| R55 analogs | Enhanced brain penetration | Lead optimization |
| NPC01 | Retromer-cargo interface | Research |
Retromer stabilizers work by:
| Compound | Company | Mechanism | Development Stage | Status |
|----------|---------|-----------|-------------------|--------|
| R55 | unknown | Direct VPS35 stabilization | Preclinical | Active |
| R33 | unknown | Enhanced brain penetration | Preclinical | Lead optimization |
| NPC01 | unknown | Retromer-cargo interface | Research | Active |
Alpha-Synuclein Models:
The retromer complex requires proper assembly for cargo recognition:
Stabilizers enhance complex integrity by:
[LRRK2](/genes/lrrk2) mutations and retromer dysfunction both affect endosomal trafficking. The pathways intersect at:
| Interaction Point | LRRK2 Effect | Retromer Effect | Combined Impact |
|------------------|--------------|-----------------|-----------------|
| Endosomal trafficking | Enhanced phosphorylation of Rab proteins | Impaired cargo sorting | Synergistic dysfunction |
| Lysosomal function | Altered trafficking | Reduced protein delivery | Lysosomal impairment |
| Autophagy | mTOR dysregulation | Impaired autophagosome formation | Reduced clearance |
[GBA](/genes/gba) mutations impair lysosomal function, which is downstream of retromer. Combined approaches may address:
The retromer interacts with mitochondrial quality control:
| Factor | Consideration |
|--------|---------------|
| Genetic status | VPS35 D620N carriers may benefit most |
| Disease stage | Early-stage patients for maximal benefit |
| Biomarkers | Elevated CSF α-synuclein, reduced lysosomal markers |
| Combination | Rationale | Expected Benefit |
|-------------|------------|------------------|
| Retromer + GBA modulators | Both enhance lysosomal function | Enhanced clearance |
| Retromer + LRRK2 inhibitors | Complementary trafficking mechanisms | Broader benefit |
| Retromer + α-synuclein antibodies | Upstream + downstream targeting | Synergistic reduction |
A landmark 2022 study developed VPS35 D620N knock-in mice that faithfully recapitulate PD phenotypes: [@chen2022]
| Finding | Description |
|---------|-------------|
| Motor deficits | Age-dependent decline in rotarod and beam walk performance |
| Alpha-synuclein pathology | Increased pSer129 aggregation in substantia nigra |
| Dopaminergic neuron loss | Progressive loss of TH+ neurons in SNpc |
| Endosomal abnormalities | Enlarged early endosomes, impaired trafficking |
| Therapeutic response | R55 treatment partially reverses phenotype |
The WASH (Wiskott-Aldrich syndrome protein and SCAR homolog) complex is essential for retromer function:
Sorting nexin (SNX) proteins coordinate retromer function with membrane remodeling:
| SNX | Function | PD Relevance |
|-----|----------|---------------|
| SNX3 | Phosphoinositide binding | Cargo recognition |
| SNX5/6 | BAR domain proteins | Membrane curvature |
| SNX27 | PDZ domain cargo recognition | Regulates glutamate receptors |
| SNX27 mutations | PD risk factor | Impaired retromer function |
| Protein | Interaction | Therapeutic Approach |
|---------|-------------|----------------------|
| TPCN2 (Two-pore channel 2) | Lysosomal Ca2+ release | Modulators enhance lysosomal function |
| SORTilin | Cargo adapter | Modulate APP processing |
| LDLR | Cargo sorting | Influence lipid metabolism |
New approaches focus on stabilizing retromer subunit interactions:
| Agent | Developer | Mechanism | Status | Notes |
|-------|-----------|-----------|--------|-------|
| R55 | -- | VPS35 stabilization | Preclinical | Validated in mouse models |
| R55-P1 | -- | Improved brain penetration | Lead optimization | PK/PD studies ongoing |
| NPC01 | -- | Retromer-cargo interface | Discovery | Hit identification |
| AAV-VPS35 | -- | Gene therapy | Preclinical | Stereotactic delivery |
Non-invasive biomarkers for retromer function are critical for clinical development:
| Biomarker | Source | Measurement | Status |
|-----------|--------|-------------|--------|
| Retromer activity | CSF | Cargo trafficking assay | Analytical validation |
| Lysosomal function | Blood | Cathepsin D activity | Exploratory |
| Alpha-synuclein clearance | CSF | pSer129/total ratio | Clinical validation |
| Endosomal size | PET | MRI contrast agents | Preclinical |
Retromer dysfunction links PD with other neurodegenerative conditions:
| Disease | Retromer Role | Shared Mechanisms |
|---------|--------------|-------------------|
| Alzheimer's disease | APP trafficking | Amyloid processing |
| Dementia with Lewy bodies | Alpha-synuclein clearance | Synucleinopathy |
| Frontotemporal dementia | TDP-43 trafficking | Protein aggregation |
| Progressive supranuclear palsy | Tau sorting | Tauopathy |
| Corticobasal degeneration | Tau and alpha-synuclein | Mixed pathology |
This cross-disease relevance makes retromer stabilization a broadly applicable therapeutic strategy.